Bayer Pharma Aktiengesellschaft

Bayer Aktiengesellschaft

Dana-Farber-Cancer Institute Inc.

The Broad Institute, Inc.

Franziska Siegel

Philip Lienau

Ulrich Lücking

Clara Christ

Nicolas Werbeck

Ulrike Sack

Daniel Hog

Knut Eis

Detlev Sülzle

Ursula Mönning

Ningshu Liu

Stefan Golz

Eckhard Bender

Daniel Basting

Ulrich Klar

Ulf Bömer

Volkhart Min-Jian Li

William Johnston Scott

Markus Berger

Ludwig Zorn

Kai Thede

Matthew Meyerson

Jens Ackerstaff

Volker Schulze

Philipp Buchgraber

Marcus Bauser

Andrea Hägebarth

Simon Holton

Kirstin Petersen

Keith Graham

Heidi Greulich

Dirk Schneider

Stephan Siegel

Florian Puehler

Dieter Moosmayer

Manfred Möwes

Anja Richter

József Bálint

Daniel Korr

Uwe Eberspächer

Michaela Bairlein

Bethany Kaplan

Hassan Youssef Harb

Phi Manh Dinh

Sarah Wagner

Eis Knut

The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).

PTEFB inhibiting macrocyclic compounds

Compounds of formula (I) processes for their production and their use as pharmaceuticals. 

4H-pyrrolo[3,2-c]pyridin-4-one derivatives

The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I). 

PTEFb inhibiting macrocyclic compounds

The present invention relates to substituted N-(phenyl-heteroaryl)-3-acetylamino-benzamides and N-[3-(acetylamino)phenyl]-phenyl-heteroaryl-carboxamides of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease such as cancer, wherein i.a.: Lrepresents an optionally substituted methylene or ethylene group; Lrepresents &#x2014;N(H)&#x2014;C(&#x2550;O)&#x2014; or &#x2014;C(&#x2550;O)&#x2014;N(H)&#x2014;; Rrepresents an optionally substituted 5- to 8-membered heterocycloalkyl, 4- to 10-membered heterocycloalkenyl, aryl, heteroaryl or &#x2014;N(R7)(Ci-C6-alkyl) group; Rrepresents an optionally substituted 5- or 6-membered heteroaryl group; Rrepresents an optionally substituted phenyl group. 

Compounds

The present invention relates to amido-substituted azole compounds of general formula (I), in which X, X, R, R, R, R, Rand Rare as defined in the claims which are inhibitors of TNKS1 and/or TNKS2, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients. 

Amido-substituted azole compounds

Growing community of inventors

Berlin, Germany

Franziska Siegel